logo Hematology/Oncology Research Studies: Open for Enrollment Date: 05/27/20


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations

NCT#/Phase: NCT03210714
Phase 2
IRB#: 2017-095b
Description: This is a subprotocol of the MATCH trial APEC1621 and is a Phase 2 trial of JNJ-42756493 (erdafitinib) in children and adolescents with recurrent or refractory solid tumors (including non-Hodgkin lymphomas, histiocytoses and CNS tumors) harboring specified activating mutations of the FGFR1/2/3/4 pathway. The study aims to determine the objective response rate of JNJ-42756493 (erdafitinib), an orally bioavailable, highly potent inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity.
Inclusion: Individuals who are between 12 months and 21 years of age and given a therapy assignment to MATCH to APEC1621B.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group
Principal Investigator(s): Carla Golden, MD
Contact(s): Diane Olszewski (510-428-3885 x 3246)
COG CRA Office (510-428-3885 x8334)
Study Link: https://clinicaltrials.gov/ct2/show/NCT03210714

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000